UBS Group’s Innovid Corp. CTV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-63,826
| Closed | -$197K | – | 11001 |
|
|
2024
Q4 | $197K | Buy |
63,826
+9,660
| +18% | +$22.8K | ﹤0.01% | 6458 |
|
|
2024
Q3 | $97.5K | Buy |
54,166
+9,990
| +23% | +$18.1K | ﹤0.01% | 6391 |
|
|
2024
Q2 | $81.7K | Buy |
44,176
+28,260
| +178% | +$60.6K | ﹤0.01% | 6326 |
|
|
2024
Q1 | $39.6K | Buy |
+15,916
| New | +$27.5K | ﹤0.01% | 6613 |
|
|
2023
Q4 | – | Sell |
-249,074
| Closed | -$319K | – | 10064 |
|
|
2023
Q3 | $319K | Buy |
249,074
+459
| +0.2% | +$537 | ﹤0.01% | 5006 |
|
|
2023
Q2 | $271K | Buy |
248,615
+24,150
| +11% | +$25.1K | ﹤0.01% | 5269 |
|
|
2023
Q1 | $316K | Buy |
224,465
+66,582
| +42% | +$122K | ﹤0.01% | 5037 |
|
|
2022
Q4 | $270K | Buy |
157,883
+216
| +0.1% | +$585 | ﹤0.01% | 5220 |
|
|
2022
Q3 | $427K | Sell |
157,667
-22
| -0% | -$63 | ﹤0.01% | 4481 |
|
|
2022
Q2 | $262K | Buy |
157,689
+81,974
| +108% | +$352K | ﹤0.01% | 4713 |
|
|
2022
Q1 | $458K | Buy |
75,715
+74,227
| +4,988% | +$407K | ﹤0.01% | 4760 |
|
|
2021
Q4 | $10K | Sell |
1,488
-494
| -25% | -$4.5K | ﹤0.01% | 8809 |
|
|
2021
Q3 | $20K | Buy |
+1,982
| New | +$19.6K | ﹤0.01% | 7166 |
|
UBS Group's CTV Position: Q1 2025 in Review
UBS Group sold out of Innovid Corp. (CTV) in Q1 2025, closing a stake of 63,826 shares — an estimated $197K sold.
UBS Group first reported a position in CTV in Q3 2021 and held it in 13 quarters. The position peaked at $458K in Q1 2022. 0 funds tracked by Wall St. Rank hold CTV as of Q1 2025.
- UBS Group reported no remaining Innovid Corp. position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 63,826 Innovid Corp. shares in Q1 2025, an estimated $197K.
- UBS Group first reported a position in Innovid Corp. in Q3 2021 and held it in 13 quarters.
- UBS Group's Innovid Corp. position peaked at $458K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Innovid Corp. as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.